Annals of Internal Medicine publishes new CDC recommendations on hepatitis C screeningAugust 17, 2012
Up to 3.9 million people in the United States are infected with HCV, a virus that can cause inflammation and permanent liver damage. The infection is most prevalent among people born from 1945 through 1965, and approximately 50 to 75 percent of those with HCV are unaware that they are infected. This is a problem because HCV progresses slowly, and the risk of serious complications increases as time passes.
The recommendation developers sought to identify testing strategies that would increase the proportion of HCV-infected persons who know their status. In particular, whether a testing strategy based on year of birth would identify persons living with HCV infection who have not been identified by risk-based testing. They conducted a systematic review of evidence published between 1995 and February 2012 to assess the prevalence of HCV and clinical outcomes. They found that the proportion of people born between 1945 and 1965 with HCV antibody was higher than that of the general population. Among that cohort, the recommendation authors found strong evidence that achieving sustained virologic response (SVR) was associated with reduced risk for death and liver cancer.
The CDC recommends that persons identified with HCV have a brief alcohol screening and intervention, as alcohol use has been shown to accelerate the progression of liver disease. The recommendation authors considered evidence from a systematic review of 22 randomized, controlled trials published since 2010 to determine the effects of a brief alcohol intervention versus no intervention on reduction of alcohol use. The research showed that patients who had a brief alcohol reduction intervention reduced their weekly alcohol consumption by an average of 38.42 grams compared with those who had no intervention.
Previously, the CDC recommended antibody screening only of individuals with health or lifestyle indicators suggesting potential infection. These indicators include a history of injecting drugs, having a blood transfusion before 1992, or being a chronic hemodialysis patient. Low case identification may result from the difficulty of implementing risk-based screening given the limited time of primary care visits and unease in discussing behavioral risks.
American College of Physicians
Related Hepatitis C Current Events and Hepatitis C News Articles
Deaths from viral hepatitis surpasses HIV/AIDS as a preventable cause of deaths in Australia
Deaths from viral Hepatitis B and C have surpassed HIV/AIDS in many countries, including Australia and in Western Europe, according to an analysis of the 2010 Global Burden of Disease study.
Breaking bad mitochondria
Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.
New data reveals positive outcomes for hepatitis C transplant patients
New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).
New combination drug therapy proves very effective in hepatitis C treatments
Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects.
Hepatitis C treatment cures over 90 percent of patients with cirrhosis
Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.
Three new studies help clarify optimal use of combination therapy in chronic hepatitis B patients
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
New data for HCV genotype 4 patients with simeprevir- and sofosbuvir-based regimens
Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients.
HIV battle must focus on hard-hit streets
When it comes to HIV, geography can be destiny, argue authors of a new article in the American Journal of Public Health.
New technique brings us closer to HIV and hepatitis C vaccines
Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research.
Hepatitis C remains major problem for HIV patients despite antiretroviral therapy
A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from antiretroviral therapy (ART) to treat HIV.
More Hepatitis C Current Events and Hepatitis C News Articles